What is keratoderma blenorrhagicum?

Keratoderma Blennorrhagicum

Keratoderma blennorrhagicum is a distinctive psoriasiform skin manifestation of reactive arthritis, characterized by pustular hyperkeratotic lesions primarily affecting the palms and soles, which is clinically and histologically indistinguishable from pustular psoriasis.

Clinical Presentation

Keratoderma blennorrhagicum presents as:

• Pustular hyperkeratotic eruptions predominantly on palms and soles 1
• Lesions that are grossly and histologically indistinguishable from pustular psoriasis 2
• Can occur in both acute and chronic phases of reactive arthritis 1
• May extend beyond palmoplantar surfaces in severe cases

Pathophysiology and Context

This condition occurs as part of reactive arthritis (formerly Reiter's syndrome), a form of spondyloarthritis that develops following infection 3, 4. Key features include:

• Triggering infections: Most commonly urogenital (especially Chlamydia trachomatis) or gastrointestinal bacterial infections 4, 5
• Latent period: Typically occurs 1-4 weeks after the inciting infection 4
• Classic triad: Conjunctivitis, urethritis, and arthritis 5

Associated Manifestations

Beyond the skin, patients may present with:

• Asymmetric oligoarthritis (predominantly lower extremities)
• Enthesitis and dactylitis
• Sacroiliitis
• Conjunctivitis or anterior uveitis
• Circinate balanitis (in males)
• Oral ulcers 4, 5

Diagnostic Considerations

Critical pitfall: Keratoderma blennorrhagicum can mimic other conditions, including:

• Pustular psoriasis (histologically identical) 3
• Monkeypox infection (in current epidemiological context) 6
• Drug-induced psoriasiform eruptions from TNF-alpha antagonists 2

Diagnostic Workup

When encountering palmoplantar pustular lesions, evaluate for:

• History of recent infection (urogenital or gastrointestinal symptoms 1-4 weeks prior)
• Joint symptoms (asymmetric oligoarthritis, especially lower extremities)
• Ocular symptoms (conjunctivitis, uveitis)
• Urogenital testing: PCR for Chlamydia trachomatis in urine and urethral swab 6
• Skin biopsy: Shows psoriasiform histology but helps exclude other diagnoses 6
• HLA-B27 testing: Associated with spondyloarthropathies

Treatment Approach

First-Line Management

1. Treat the triggering infection - This is the primary therapeutic goal 4

   • Antibiotics for Chlamydia trachomatis if identified
   • Appropriate antimicrobials for documented gastrointestinal pathogens

2. For arthritis symptoms:

   • NSAIDs as first-line 4
   • Intraarticular or oral glucocorticosteroids as second-line 4

Refractory Skin Disease

When keratoderma blennorrhagicum persists despite conventional treatment:

• DMARDs: Sulfasalazine is the traditional choice 1, 4

• Biologic therapy: TNF-alpha inhibitors are used for refractory cases 4

  • Important caveat: TNF-alpha antagonists can paradoxically induce psoriasiform eruptions in some patients, potentially related to reactivation of Chlamydia 2

• JAK inhibitors: Tofacitinib has shown remarkable efficacy for severe keratoderma blennorrhagicum refractory to conventional DMARDs and biologics, with significant improvement within 20 days 1

Treatment Algorithm for Severe Skin Involvement

1. Confirm and treat underlying infection
2. If skin lesions persist: Sulfasalazine or thalidomide
3. If inadequate response: Consider TNF-alpha inhibitors (adalimumab, others)
4. If skin worsens on biologics: Switch to tofacitinib 1

Prognosis

• >50% have self-limited course lasting 2-6 months 4
• 30% experience recurrent episodes 4
• 10-20% develop chronic disease requiring immunosuppressive therapy 4
• 15-20% may develop severe chronic sequelae 5

The presence of keratoderma blennorrhagicum indicates more severe reactive arthritis and may predict a more protracted course requiring systemic immunosuppression.